During the past decade, Porubcin, Michael MD (UIA Investigator) conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 40 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 15 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Porubcin, Michael MD (UIA Investigator)" #1 sponsor was "National Cancer Institute (NCI)" with 38 trials, followed by "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "SWOG Cancer Research Network" with 5 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 4 trials sponsored and "NSABP Foundation Inc" with 4 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Porubcin, Michael MD (UIA Investigator)" #1 collaborator was "National Cancer Institute (NCI)" with 16 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator and "North Central Cancer Treatment Group" with 3 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Porubcin, Michael MD (UIA Investigator)" are "Adult Giant Cell Glioblastoma" (3 trials), "Adult Glioblastoma" (3 trials), "Adult Gliosarcoma" (3 trials), "Breast Cancer" (3 trials) and "Clear Cell Renal Cell Carcinoma" (3 trials). Many other conditions were trialed in "Porubcin, Michael MD (UIA Investigator)" in a lesser frequency.

Most popular intervention types in "Porubcin, Michael MD (UIA Investigator)" are "Drug" (50 trials), "Other" (34 trials), "Biological" (24 trials), "Radiation" (7 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (28 trials), "Bevacizumab" (14 trials), "Quality-of-Life Assessment" (11 trials), "Paclitaxel" (8 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "Porubcin, Michael MD (UIA Investigator)" are 44 trials for "All" genders, 8 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Porubcin, Michael MD (UIA Investigator)". undefined are not yet recruiting, undefined are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Porubcin, Michael MD (UIA Investigator), undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Porubcin, Michael MD (UIA Investigator), 4 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".